PROSEEK study shows no treatment benefit of Vodobatinib in patients with early Parkinson’s Disease Read more
SPARC completes enrolment in PROSEEK, Phase 2 study of Vodobatinib in early Parkinson’s disease Read more
Sun Pharma and SPARC enter into licence agreement for commercialisation of phenobarbital for injection in US Read more